A Study of OV101 in Individuals With Angelman Syndrome (AS)
Trial details
- Registry ID
- NCT04106557
- Drugs studied
- Gaboxadol
TrialRedline tracks 2 clinical trials sponsored by Ovid Therapeutics Inc.: 1 Phase 3, 1 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study of OV101 in Individuals With Angelman Syndrome (AS)NCT04106557 | Gaboxadol | Completed | 2020-11-02Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study of OV101 in Individuals With Fragile X SyndromeNCT03697161 | OV101 (gaboxadol) | Completed | 2020-02-03Actual |
Names as written in the registry records.